MICB and neoplasm: Recently, NKG2D ligand (MICA and MICB) α3 domain-specific antibodies were developed to restore NK cell-mediated tumor immunity by increasing the density of stimulatory MICA and MICB ligands on the surface of tumor cells along with reducing the shedding of both MICA and MICB.236 Therefore, targeting co-stimulatory receptor signaling may serve as an alternative strategy to boost NK cell function and prove beneficial for cancer treatment (Fig. 3).